A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB).
Epistemonikos ID: 0d521b17f1e1170711f21438bcb8c7ba08064c89
First added on: May 10, 2024